UNC School of Pharmacy

Research Highlights

 

Research Highlights

The following example bioactive compounds discovered by the NPRL are currently in
clinical trials or preclinical studies:

  1. GL-331, a synthetic etoposide analog developed in the NPRL, was in Phase II clinical trial as an anticancer drug.
  2. Bevirimat (PA-457, DSB), a modified triterpene natural product, licensed previously to Panacos Pharmaceuticals, Inc. and now to Myriad Pharmaceutical Company, has succeeded in Phase IIa anti-AIDS clinical trials.  Phase III clinical trials plan to begin in 2009/2010, following the completion of Phase IIb clinical trials.  Bevirimat is a first-in-class maturation inhibitor.
  3. Novel curcumin analogs discovered and developed in the NPRL were licensed to AndroScience Corporation of San Diego, CA.  One compound, JC-9, is currently in a Phase II clinical trial for treating acne. JC-9 is planned for a clinical trial for prostate cancer in the near future.
  4. Preclinical studies on numerous novel promising natural product-based leads including DCP analogs as anti-AIDS agents as well as analogs of tylophorine and neotanshinlactone as drugs for treating lung and breast cancers are in progress.
Document Actions